Methods and compounds for restoring mutant p53 function

Inventors

Vu, Binh • Dominique, Romyr • Li, Hongju • Fahr, Bruce • Good, Andrew

Assignees

PMV Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12428406-B2

Patent

Publication Date

2025-09-30

Expiration Date


Abstract

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Core Innovation

The invention is a method of treating a cancer that expresses the p53 mutant p53 Y220C by administering to a subject in need thereof a therapeutically effective amount of a compound of the recited formula, or a pharmaceutically acceptable salt thereof. The formula specifies R1 as alkyl substituted with NR16R17, R2 as substituted alkyl, R3 and R13 as hydrogen, and R4 as aryl, heteroaryl, or heterocyclyl substituted with at least halo.

The described compounds bind mutant p53, including p53 Y220C, and increase or restore wild-type activity. For p53 Y220C, binding is proposed to occupy and stabilize the cavity created by the mutation, promoting a biologically active conformation, DNA binding, and downstream tumor-suppressive effects, and potentially inducing apoptosis. A Formula (I) embodiment is described with an SC150 value below 1 μM for p53 Y220C by HTRF assay.

The examples are indole-alkyne compounds, predominantly 1-(2,2,2-trifluoroethyl)indoles and related fused heterocycles, with varied amine, piperidine, spirocyclic, sulfonyl, sulfonamide, amide, and carboxylate substituents, including stereoisomers. These serve as chemical exemplification of the claimed compound genus. The supplied content omits the background section, so the problem addressed is not explicitly described in patent.

Claims Coverage

The claims identify one independent claim, claim 1, directed to a method of treating cancer expressing p53 Y220C with a formula-defined compound or a pharmaceutically acceptable salt thereof. Three inventive features are identified.

Treatment of cancer expressing p53 Y220C

A method of treating a cancer that expresses the p53 mutant p53 Y220C by administering to a subject in need thereof a therapeutically effective amount of the claimed compound.

Formula-defined compound and substituent scope

The compound has the recited formula: R1 is alkyl substituted with NR16R17, R2 is substituted alkyl, R3 and R13 are hydrogen, and R4 is aryl, heteroaryl, or heterocyclyl, each substituted with at least halo. The claim also defines the permitted groups for R16, R17, R21, and R22.

Pharmaceutically acceptable salt

The claim also covers a pharmaceutically acceptable salt of the compound.

The independent claim combines treatment of cancer expressing p53 Y220C with administration of a therapeutically effective amount of a structurally defined compound or its pharmaceutically acceptable salt. Dependent claims narrow compound substituents and specify cancer types, including ovarian cancer, as well as dose range, administration routes including oral administration, and a human subject.

Stated Advantages

The compounds bind mutant p53 and increase or restore its wild-type activity, promoting a biologically active conformation and DNA binding, and potentially inducing apoptosis.

Binding and stabilizing the cavity created by the p53 Y220C mutation is described as restoring DNA binding and downstream tumor-suppressive effects.

A halo substituent (stated as a heterocyclyl halo substituent) provides at least about 50% greater oral bioavailability than an analogous compound lacking that substituent.

The summary reports evaluation of stabilization of p53 Y220C and enhancement of its DNA-binding activity.

Documented Applications

Treatment of cancer expressing the p53 Y220C mutant, including ovarian cancer (identified in a dependent claim) and breast and lung cancers (identified as treatment embodiments in the description).

Induction of apoptosis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.